Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9003866 | 1.00 | TDP1 (0.40) | TDP1SMN1; SMN2SLC22A6FOLH1LMNA | |
| SCHEMBL8711551 | 1.00 | TDP1 (0.40) | TDP1SMN1; SMN2SLC22A6FOLH1LMNA | |
| Water SCHEMBL28069402 | 0.98 | TDP1 (0.39) | TDP1SMN1; SMN2SLC22A6FOLH1LMNA | |
| SCHEMBL12483314 | 0.82 | PMP22 (0.35) | LMNACYP3A4TSHRHIF1AHSD17B10 | |
| SCHEMBL10654850 | 0.82 | PMP22 (0.35) | LMNACYP3A4TSHRHIF1AHSD17B10 | |
| SCHEMBL28261895 | 0.81 | CPA1 (0.44) | FOLH1MAPT | |
| Water SCHEMBL28286387 | 0.80 | PMP22 (0.34) | LMNACYP3A4TSHRHIF1AHSD17B10 | |
| SCHEMBL11158578 | 0.80 | CYP3A4 (0.31) | LMNACYP3A4TSHRHIF1AHSD17B10 | |
| SCHEMBL11155839 | 0.80 | CYP3A4 (0.35) | LMNACYP3A4TSHRHIF1AHSD17B10 | |
| SCHEMBL5630344 | 0.79 | TDP1 (0.39) | TDP1SMN1; SMN2SLC22A6FOLH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109010830-A | Application of the blood platelet related inhibitors in preparation treatment decrease of platelet disease drug | 苏州大学 | 2018-12-18 | — | — | CN | claimed |
| CN-1889974-A | Oligopeptides as coating material for medical products | HEMOTEQ GMBH (DE) | 2007-01-03 | — | — | CN | claimed |
| CN-105218685-B | The anion polysaccharide being functionalized by least two hydrophobic groupings as entrained by the spacer of at least trivalent | 阿道恰公司 | 2018-12-25 | — | — | CN | disclosed |
| CN-109010830-A | Application of the blood platelet related inhibitors in preparation treatment decrease of platelet disease drug | 苏州大学 | 2018-12-18 | — | — | CN | disclosed |
| CN-105498838-B | A kind of Baeyer Villiger oxidation reaction catalysts and preparation method and application | 石家庄学院 | 2017-11-21 | — | — | CN | disclosed |
| CN-105218685-A | Functionalized anionic polysaccharide is carried out by least two hydrophobic groupings entrained by the spacer of at least trivalent | ADOCIA | 2016-01-06 | — | — | CN | disclosed |
| CN-102834117-B | Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer | ADOCIA (FR) | 2015-11-25 | — | — | CN | disclosed |
| US-9115218-B2 | Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer | ADOCIA (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140051706-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM PHARMA CO., LTD. (JP) | 2014-02-20 | — | — | US | disclosed |
| CN-103517904-A | Alpha-helix mimetics and methods relating thereto | PRISM BIOLAB CORP | 2014-01-15 | — | — | CN | disclosed |
| CN-102834117-A | Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer | ADOCIA | 2012-12-19 | — | — | CN | disclosed |
| CN-1889974-B | Oligopeptides as coating material for medical products | HEMOTEQ GMBH | 2012-08-29 | — | — | CN | disclosed |
| US-20110195913-A1 | Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer | ADOCIA (FR) | 2011-08-11 | — | — | US | disclosed |
| CN-101595103-A | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | CN | disclosed |
| CN-101098852-A | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof | SMITHKLINE BEECHAM CORP (US) | 2008-01-02 | — | — | CN | disclosed |
| CN-1889974-A | Oligopeptides as coating material for medical products | HEMOTEQ GMBH (DE) | 2007-01-03 | — | — | CN | disclosed |
| CN-85101227-A | The preparation method of novel alpha-chlorinated carbonates and application | — | 1987-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051706-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | TDP1 1347/4885SMN1; SMN2 1746/4885SLC22A6 4056/4885 |
| US-20110195913-A1 | Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer | CD44, CSGALNACT1, ALG1 | TDP1 4396/4885SMN1; SMN2 3497/4885SLC22A6 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.